The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Similar to others, I don't see any offers coming until we have much more trial data...
Also, does Sath have any shares/options? I don't see any mention. I suspect no CFO would sit out buying shares/receiving options - if a partnership deal/TO was in the offing (obviously taking into account, quiet periods & access to information).. If we see Sath take up some shares/options when he is able to do so, that is a solid sign...
thanks tf, yes, those were fun times, sp spiking to almost 60p on moditope (admittedly, far fewer shares in issue)...
$10bn - my simpleton back of a *** packet, can't see why a major pharma would pay that for where we are even if scib1 trial is wildly successful, they could acquire us for far less. i could see that happening if we had multiple successful ph2 trials completed and 1 major ph3 in progress/planned..
i think someone cited, 5.5x potential sales as a valuation multiple. if we just took scib1 and assumed success and iscib then providing acess to all the patient population what could that be - assuming 20% of melanoma sales were scib?
Given the 1.2Bn shares in circulation (CLN's) when fully diluted, I was tinkering with valuations/outcomes.
What's to stop Moderna acquiring SCLP and then mothballing SCIB 1 - in favour of their own more mature 'personalized approach'???
SCIB 1 seems to be the only driving factor for a partnership or outright acquisition I can foresee - this of course assumes a successful trial in 40+ patients.
I've been an investor here since 2012, with an ave. far higher than 11p. I think some of the figures discussed in the days of Puritas, now seem a little far fetched - 4, 8, 12 etc...
Time will tell I suppose.
Fair play Crumbs, you did indeed call this. Enjoy your day. I'm just glad I took the inertia approach, didn't sell any of mine. Did bottle a top up at 9p tho, but c'est la vie, been here 12yrs and very willing to wait another 18-24mths to let things unfold.
I also would love to see milestone progress with Genmab, but never underestimate the lethargy within large complex organizations. Their upfront is only $5m, they can sit on this for a few years... Would love to be wrong and hear it's moving at pace, but I suspect not, all IMHO.
Reflecting on the RNS, I was somewhat dissapointed at first glance. However, that was probably more to do with my entirely unrealistic expectations of what they would share ref Modi-1. It's super early, I am now at peace to sit and wait for 6-9 mths and allow clinical updates on Modi-1 to come through when Scancell is good and ready...
Good dose of reality here. Scancell if they have outstanding results in trials, will partner or (if we are lucky) evalute a takeover offer. They are not set up (scale or distribution expertise).